GDTC insider trading — CytoMed Therapeutics Ltd
Over the last 90 days, insiders at CytoMed Therapeutics Ltd (GDTC) made 2 open-market purchases worth $300K and 0 open-market sales worth $0, making them net buyers by $300K. The largest purchase was by Choo Chee Kong (Director), who bought 100,000 shares for $150K on Jul 20, 2026.
Updated Oct 16, 2026.
Recent GDTC insider transactions
Every Form 4 filed by CytoMed Therapeutics Ltd officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | Choo Chee Kong | Director | P · Purchase | Direct | 100,000 | $1.50 | $150K | Form 4 |
| Jul 14, 2026 | Choo Chee Kong | Director | P · Purchase | Direct | 100,000 | $1.50 | $150K | Form 4 |
GDTC insider trading FAQ
Are insiders buying GDTC stock?
Yes. In the last 90 days, CytoMed Therapeutics Ltd insiders made 2 open-market purchases totaling $300K, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading GDTC?
Recent buyers: Choo Chee Kong.
Where does GDTC insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.